Amylin and Takeda Advance Development of New Obesity Treatment


Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that following positive phase 2 study results in a new obesity treatment, they will  advance towards phase 3 development of a combination treatment for obesity which includes pramlintide (an analog of the natural hormone amylin)  and metreleptin  (an analog of the natural hormone leptin). The phase 2 results demonstrated sustained weight loss over a 52 week period.

In November 2009 the two companies announced an agreement to co-develop and commercialize pharmaceutical products for the treatment of obseity and related conditions.

Leave a Reply

1 Comment threads
0 Thread replies
Most reacted comment
Hottest comment thread
1 Comment authors
Lisa Jackson Recent comment authors
newest oldest most voted
Notify of
Lisa Jackson
Lisa Jackson

I m a type 1 who had gained over 50lbs when first starting on insulin.I was put on the synthetic for Amylin called Symlin and lost 15lbs in the first 2wks. Because diabetics have been found to be missing this additional hormone, replacing it seems logical.

Copyright © 2009-2018 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.